Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 3/2014

01.09.2014 | short review

The role of maintenance strategies in breast cancer

verfasst von: Elisabetta Munzone, MD, Marco Colleoni, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Maintenance treatment is generally administered to patients without progression after an initial chemotherapy regimen of standard duration, with the aim of increasing the time to progression of disease. The aims of this strategy include prolongation of survival with good quality of life and symptom control. The duration of the treatment is generally based on patient responsiveness and individual tolerability as well as physician preferences. As breast cancer is a heterogeneous disease with different biological characteristics, the strategy of maintenance therapy may be adapted accordingly. Metronomic chemotherapy has been investigated particularly in advanced hormone receptor negative breast cancer and resulted as an interesting and valid alternative for maintenance therapy in this setting of patients. Recent results of a meta-analysis of randomized trials with maintenance chemotherapy showed a slight benefit in the overall survival and a more significant benefit in the progression free survival. However, this benefit should be balanced with toxicities and the use of the regimen with the best risk-benefit ratio should be preferred. Communication between the oncologist and the patient may help to determine the appropriate treatment choice and the correct duration of the treatment on an individual basis.
Literatur
1.
2.
Zurück zum Zitat Sánchez-Muñoz A, Pérez-Ruiz E, Ribelles N, Márquez A, Alba E. Maintenance treatment in metastatic breast cancer. Expert Rev Anticancer Ther. 2008;8(12):1907–12.PubMedCrossRef Sánchez-Muñoz A, Pérez-Ruiz E, Ribelles N, Márquez A, Alba E. Maintenance treatment in metastatic breast cancer. Expert Rev Anticancer Ther. 2008;8(12):1907–12.PubMedCrossRef
3.
Zurück zum Zitat Stockler MR, Wilcken NJC, Coates AS. Chemotherapy for advanced breast cancer: How long should it continue? Breast Cancer Res Treat. 2003;81(suppl 1):S49–52.CrossRef Stockler MR, Wilcken NJC, Coates AS. Chemotherapy for advanced breast cancer: How long should it continue? Breast Cancer Res Treat. 2003;81(suppl 1):S49–52.CrossRef
4.
Zurück zum Zitat Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast. 2012 Jun;21(3):242–52.PubMedCrossRef Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast. 2012 Jun;21(3):242–52.PubMedCrossRef
5.
Zurück zum Zitat Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010;7:455–65.PubMedCrossRef Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010;7:455–65.PubMedCrossRef
6.
Zurück zum Zitat Munzone E, Bertolini F, Colleoni M. Part III. Clinical activity of metronomic chemotherapy: Breast cancers. In: Giulio F, Bocci G, editors. Metronomic Chemotherapy: pharmacology and clinical applications. :Springer; 2014. (in press). Munzone E, Bertolini F, Colleoni M. Part III. Clinical activity of metronomic chemotherapy: Breast cancers. In: Giulio F, Bocci G, editors. Metronomic Chemotherapy: pharmacology and clinical applications. :Springer; 2014. (in press).
7.
Zurück zum Zitat Coates A, Gebski V, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med. 1987;317(24):1490–5.PubMedCrossRef Coates A, Gebski V, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med. 1987;317(24):1490–5.PubMedCrossRef
8.
Zurück zum Zitat Harris AL, Cantwell BM, Carmichael J, et al. Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet. 1990;335(8683):186–90.PubMedCrossRef Harris AL, Cantwell BM, Carmichael J, et al. Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet. 1990;335(8683):186–90.PubMedCrossRef
9.
Zurück zum Zitat Muss HB, Case LD, Richards F, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med. 1991;325(19):1342–8.PubMedCrossRef Muss HB, Case LD, Richards F, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med. 1991;325(19):1342–8.PubMedCrossRef
10.
Zurück zum Zitat Ejlertsen B, Pfeiffer P, Pedersen D, et al. Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18–6 months. Eur J Cancer. 1993;29A(4):527–31.PubMedCrossRef Ejlertsen B, Pfeiffer P, Pedersen D, et al. Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18–6 months. Eur J Cancer. 1993;29A(4):527–31.PubMedCrossRef
11.
Zurück zum Zitat Gregory RK, Powles TJ, Chang JC, Ashley S. A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur J Cancer. 1997;13:2194–7.CrossRef Gregory RK, Powles TJ, Chang JC, Ashley S. A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur J Cancer. 1997;13:2194–7.CrossRef
12.
Zurück zum Zitat Falkson G, Gelman RS, Pandya KJ, et al. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol. 1998;5:1669–76. Falkson G, Gelman RS, Pandya KJ, et al. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol. 1998;5:1669–76.
13.
Zurück zum Zitat Nooij MA, de Haes JC, Beex LV, Wildiers J, Klijn J, Becquart D, Jassem J, Engelsman E, Duchateau L. EORTC Breast Cancer Group. Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. Clinical outcomes and oncologists’ preferences. Eur J Cancer. 2003;5:614–21.CrossRef Nooij MA, de Haes JC, Beex LV, Wildiers J, Klijn J, Becquart D, Jassem J, Engelsman E, Duchateau L. EORTC Breast Cancer Group. Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. Clinical outcomes and oncologists’ preferences. Eur J Cancer. 2003;5:614–21.CrossRef
14.
Zurück zum Zitat Gennari A, Amadori D, De Lena M, et al. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol. 2006;24(24):3912–8.PubMedCrossRef Gennari A, Amadori D, De Lena M, et al. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol. 2006;24(24):3912–8.PubMedCrossRef
15.
Zurück zum Zitat Alba E, Ruiz-Borrego M, Margeli M, et al. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001–01 study. Breast Cancer Res Treat. 2010;122(1):169–76.PubMedCrossRef Alba E, Ruiz-Borrego M, Margeli M, et al. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001–01 study. Breast Cancer Res Treat. 2010;122(1):169–76.PubMedCrossRef
16.
Zurück zum Zitat Park YH, Jung KH, Im S-A, et al. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel (KCSG-BR07–02) as first-line chemotherapy. J Clin Oncol. 2013;31:1732–9.PubMedCrossRef Park YH, Jung KH, Im S-A, et al. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel (KCSG-BR07–02) as first-line chemotherapy. J Clin Oncol. 2013;31:1732–9.PubMedCrossRef
17.
Zurück zum Zitat Martín M, López-Tarruella S. Chemotherapy: Maintenance therapy in breast cancer—many questions remain. Nat Rev Clin Oncol. 2013;10,370–2.PubMedCrossRef Martín M, López-Tarruella S. Chemotherapy: Maintenance therapy in breast cancer—many questions remain. Nat Rev Clin Oncol. 2013;10,370–2.PubMedCrossRef
18.
Zurück zum Zitat Gennari A, Stockler M, Puntoni M, Sormani M, Nanni O, Amadori D, Wilcken N, D’Amico M, DeCensi A, Bruzzi P. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials J Clin Oncol. 2011;9(16):2144–9.CrossRef Gennari A, Stockler M, Puntoni M, Sormani M, Nanni O, Amadori D, Wilcken N, D’Amico M, DeCensi A, Bruzzi P. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials J Clin Oncol. 2011;9(16):2144–9.CrossRef
19.
Zurück zum Zitat Lim S, Lee S, Han J, Park BW, Kim S, Park S, Kim JH, Choi HJ, Sohn J. Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer. Breast. 2013;22(6):1205–9.PubMedCrossRef Lim S, Lee S, Han J, Park BW, Kim S, Park S, Kim JH, Choi HJ, Sohn J. Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer. Breast. 2013;22(6):1205–9.PubMedCrossRef
20.
Zurück zum Zitat Dufresne A, Pivot X, Tournigand C, et al. Maintenance hormonal treatment improves progression free survival after a first line chemotherapy in patients with metastatic breast cancer. Int J Med Sci. 2008 May 5;5(2):100–5.PubMedCrossRefPubMedCentral Dufresne A, Pivot X, Tournigand C, et al. Maintenance hormonal treatment improves progression free survival after a first line chemotherapy in patients with metastatic breast cancer. Int J Med Sci. 2008 May 5;5(2):100–5.PubMedCrossRefPubMedCentral
21.
Zurück zum Zitat Fabi A, Russillo M, Ferretti G, Metro G, Nisticò C, Papaldo P, De Vita F, D’Auria G, Vidiri A, Giannarelli D, Cognetti F. Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy. BMC Cancer. 2012;12:482.PubMedCrossRefPubMedCentral Fabi A, Russillo M, Ferretti G, Metro G, Nisticò C, Papaldo P, De Vita F, D’Auria G, Vidiri A, Giannarelli D, Cognetti F. Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy. BMC Cancer. 2012;12:482.PubMedCrossRefPubMedCentral
22.
Zurück zum Zitat Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002;3(1):73–80.CrossRef Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002;3(1):73–80.CrossRef
23.
Zurück zum Zitat Orlando L, Cardillo A, Rocca A, et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anti-Cancer Drugs. 2006;17:961–7.PubMedCrossRef Orlando L, Cardillo A, Rocca A, et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anti-Cancer Drugs. 2006;17:961–7.PubMedCrossRef
24.
Zurück zum Zitat Wang Z, Lu J, Leaw S, et al. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study. Cancer Chemother Pharmacol. 2012;69(2):515–22.PubMedCrossRef Wang Z, Lu J, Leaw S, et al. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study. Cancer Chemother Pharmacol. 2012;69(2):515–22.PubMedCrossRef
25.
Zurück zum Zitat Munzone E, Di Pietro A, Goldhirsch A, et al. Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report. Breast. 2010;19(1):33–7.PubMedCrossRef Munzone E, Di Pietro A, Goldhirsch A, et al. Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report. Breast. 2010;19(1):33–7.PubMedCrossRef
26.
Zurück zum Zitat Addeo R, Sgambato A, Cennamo G, et al. Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clin Breast Cancer. 2010;10(4):301–6.PubMedCrossRef Addeo R, Sgambato A, Cennamo G, et al. Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clin Breast Cancer. 2010;10(4):301–6.PubMedCrossRef
27.
Zurück zum Zitat Goss PE, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol. 2008;26(12):1948–55.PubMedCrossRef Goss PE, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol. 2008;26(12):1948–55.PubMedCrossRef
28.
Zurück zum Zitat Cuzick J, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135–41.PubMedCrossRef Cuzick J, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135–41.PubMedCrossRef
29.
Zurück zum Zitat Davies C, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–16.PubMedCrossRefPubMedCentral Davies C, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–16.PubMedCrossRefPubMedCentral
30.
Zurück zum Zitat Gray RG, Rea D, Handley K, et al. ATTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer. J Clin Oncol. 2013;31((suppl) abstr 5): . Gray RG, Rea D, Handley K, et al. ATTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer. J Clin Oncol. 2013;31((suppl) abstr 5): .
31.
Zurück zum Zitat Levine MN, Gent M, Hryniuk WM, et al. A randomized trial comparing 12 weeks with 36 weeks of adjuvant chemotherapy in stage II breast cancer. J Clin Oncol. 1990;8:1217–25.PubMed Levine MN, Gent M, Hryniuk WM, et al. A randomized trial comparing 12 weeks with 36 weeks of adjuvant chemotherapy in stage II breast cancer. J Clin Oncol. 1990;8:1217–25.PubMed
32.
Zurück zum Zitat Senn HJ, Jungi WF. Swiss adjuvant trials with LMF ( + BCG) in N- and N + breast cancer patients. In: Salmon SE, editor. Adjuvant therapy of cancer IV. Orlando: Grune & Stratton; 1984; pp 261–70. Senn HJ, Jungi WF. Swiss adjuvant trials with LMF ( + BCG) in N- and N + breast cancer patients. In: Salmon SE, editor. Adjuvant therapy of cancer IV. Orlando: Grune & Stratton; 1984; pp 261–70.
33.
Zurück zum Zitat Falkson HC, Gray R, Wolberg WH, Gillchrist KW, Harris JE, Tormey DC, Falkson G. Adjuvant therapy of post-menopausal women with breast cancer: an ECOG phase III study. J Clin Oncol. 1989;8:599–607. Falkson HC, Gray R, Wolberg WH, Gillchrist KW, Harris JE, Tormey DC, Falkson G. Adjuvant therapy of post-menopausal women with breast cancer: an ECOG phase III study. J Clin Oncol. 1989;8:599–607.
Metadaten
Titel
The role of maintenance strategies in breast cancer
verfasst von
Elisabetta Munzone, MD
Marco Colleoni, MD
Publikationsdatum
01.09.2014
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0159-3

Weitere Artikel der Ausgabe 3/2014

memo - Magazine of European Medical Oncology 3/2014 Zur Ausgabe